JONATHAN OSBURN: Open Payments
NPI 1265468862 · BRIDGMAN, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$648 in 37 payments from 14 companies in 2025. Trend: 2023 $655 · 2024 $606 · 2025 $648
Food & beverage: $648
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 10 | $137 |
| Novo Nordisk Inc | 5 | $107 |
| AstraZeneca Pharmaceuticals LP | 6 | $96 |
| PFIZER INC. | 2 | $48 |
| Astellas Pharma US Inc | 2 | $43 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $35 |
| Eisai Inc. | 2 | $35 |
| ABBVIE INC. | 2 | $32 |
| Novartis Pharmaceuticals Corporation | 1 | $26 |
| Dexcom, Inc. | 1 | $21 |
Products named: TRELEGY ELLIPTA, Wegovy, FARXIGA, ELIQUIS, Veozah, SHINGRIX, JARDIANCE, Leqembi.
Industry payments across MI — which companies pay providers there.
